Semaglutide vs Liraglutide
Semaglutide and liraglutide are both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) used in type 2 diabetes and obesity management, but they differ substantially in pharmacokinetic design, dosing convenience, and clinical potency. Semaglutide incorporates structural modifications that extend its half-life by an order of magnitude, enabling once-weekly dosing and superior metabolic outcomes.
Structural and Mechanistic Differences
Section titled “Structural and Mechanistic Differences”Liraglutide
Section titled “Liraglutide”Liraglutide is a 31-amino acid analogue of native GLP-1(7-37) with two key modifications: substitution of Ala34 with Arg, and attachment of a C-16 fatty palmitoyl acyl chain via a glutamic acid spacer to Lys26. The fatty acylation promotes non-covalent self-association at subcutaneous injection sites and albumin binding in plasma, extending the half-life to approximately 13 hours — sufficient for once-daily administration.
Liraglutide activates the GLP-1R with an EC₅₀ of ~0.2 nM, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety via hypothalamic circuits.
Semaglutide
Section titled “Semaglutide”Semaglutide builds on liraglutide’s design with three additional modifications: Aib (α-aminoisobutyric acid) substitution at position 8 protects against DPP-4 enzymatic degradation, Arg34 replaces Lys34, and a C-18 fatty diacid chain (rather than palmitic acid) is conjugated to Lys26 via a mini-PEG linker. The diacid moiety confers stronger albumin binding and the Aib substitution blocks the primary DPP-4 cleavage site, extending the half-life to approximately 165 hours (7 days).
This pharmacokinetic improvement enables once-weekly dosing and achieves higher steady-state plasma concentrations, translating to greater receptor occupancy and more potent metabolic effects.
Comparison Table
Section titled “Comparison Table”| Property | Semaglutide | Liraglutide |
|---|---|---|
| Amino acid count | 31 | 31 |
| Fatty acid moiety | C-18 diacid | C-16 palmitoyl |
| Position 8 modification | Aib (DPP-4 resistant) | Ala (native) |
| Albumin binding | Very high | High |
| Half-life | ~165 hrs (7 days) | ~13 hrs |
| Dosing frequency | Once weekly | Once daily |
| GLP-1R EC₅₀ | ~0.2 nM | ~0.2 nM |
| Bioavailability | ~89% | ~55% |
Pharmacokinetics
Section titled “Pharmacokinetics”The half-life difference is the defining pharmacological distinction. Semaglutide’s 165-hour half-life produces a steady state after 4–5 weeks of once-weekly dosing, with peak-to-trough ratios of approximately 2:1. Liraglutide’s 13-hour half-life requires daily injection but achieves steady state within 2–3 days, with more pronounced peak-trough fluctuations.
Bioavailability is substantially higher for semaglutide (~89%) versus liraglutide (~55%), though both are administered subcutaneously. The higher bioavailability of semaglutide contributes to more predictable exposure across patients.
Weight Loss Efficacy
Section titled “Weight Loss Efficacy”Semaglutide (STEP Trials)
Section titled “Semaglutide (STEP Trials)”The STEP program evaluated semaglutide 2.4 mg weekly for obesity:
- STEP-1: 14.9% body weight loss at 68 weeks vs. 2.4% with placebo
- STEP-2: 9.6% weight loss in obese patients with T2D vs. 3.4% placebo
- STEP-3: 16.0% with intensive behavioral therapy vs. 5.7% placebo
Liraglutide (SCALE Trials)
Section titled “Liraglutide (SCALE Trials)”The SCALE program evaluated liraglutide 3.0 mg daily for obesity:
- SCALE-1: 8.0% body weight loss at 56 weeks vs. 2.6% with placebo
- SCALE-2: 6.0% weight loss in T2D patients vs. 2.0% placebo
- SCALE-3: 10.6% with intensive behavioral therapy vs. 4.8% placebo
Semaglutide 2.4 mg achieves nearly double the weight loss of liraglutide 3.0 mg, driven by higher receptor occupancy, more sustained GLP-1R activation, and greater appetite suppression at the hypothalamic level.
HbA1c Reduction
Section titled “HbA1c Reduction”| Dose | Semaglutide HbA1c Reduction | Liraglutide HbA1c Reduction |
|---|---|---|
| Low dose | ~1.0% (0.5 mg weekly) | ~0.8% (0.6 mg daily) |
| Mid dose | ~1.5–1.8% (1.0 mg weekly) | ~1.0–1.2% (1.2 mg daily) |
| Max dose | ~2.0% (2.0 mg weekly) | ~1.3–1.5% (1.8 mg daily) |
Both agents achieve clinically meaningful HbA1c reductions, but semaglutide’s dose-response curve extends further. In the SUSTAIN trial program, semaglutide 1.0 mg weekly demonstrated HbA1c reductions of 1.5–1.8%, while liraglutide 1.8 mg daily achieved 1.0–1.2% reductions. The SUSTAIN-7 trial directly compared semaglutide 0.5/1.0 mg weekly to liraglutide 1.2/1.8 mg daily, demonstrating superior HbA1c and weight loss with semaglutide at both matched dose levels.
Injection Site Reactions and Tolerability
Section titled “Injection Site Reactions and Tolerability”Both agents share the GLP-1 RA class side effect profile: nausea (20–44%), diarrhea (12–30%), vomiting (8–24%), and decreased appetite. Injection site reactions occur at similar rates (1–7%).
Key differences:
- Semaglutide may cause more initial nausea due to higher peak concentrations, though the weekly dosing allows more gradual adaptation
- Liraglutide’s daily dosing results in more frequent, lower-amplitude GI symptoms
- Both carry boxed warnings for thyroid C-cell tumors (rodent data, human relevance uncertain)
- Pancreatitis signal remains low for both agents in post-marketing surveillance
Cost and Access
Section titled “Cost and Access”| Factor | Semaglutide | Liraglutide |
|---|---|---|
| Brand names | Ozempic (diabetes), Wegovy (obesity) | Victoza (diabetes), Saxenda (obesity) |
| List price (monthly) | ~$935–1,350 | ~$850–1,200 |
| Insurance coverage | Broadly covered | Broadly covered |
| Injection frequency | Once weekly | Once daily |
| Adherence advantage | Fewer injections | — |
Weekly dosing with semaglutide provides a significant adherence advantage. Studies consistently demonstrate that injection frequency inversely correlates with medication adherence, and once-weekly regimens improve persistence compared to daily injections.
Clinical Evidence Summary
Section titled “Clinical Evidence Summary”| Trial | Drug | Dose | Primary Endpoint | Result |
|---|---|---|---|---|
| STEP-1 | Semaglutide | 2.4 mg/wk | Weight loss at 68 wk | 14.9% vs 2.4% |
| STEP-2 | Semaglutide | 2.4 mg/wk | Weight loss (T2D) | 9.6% vs 3.4% |
| SCALE-1 | Liraglutide | 3.0 mg/day | Weight loss at 56 wk | 8.0% vs 2.6% |
| SCALE-2 | Liraglutide | 3.0 mg/day | Weight loss (T2D) | 6.0% vs 2.0% |
| SUSTAIN-7 | Both | Various | HbA1c, weight | Semaglutide superior |
When to Choose Which
Section titled “When to Choose Which”Semaglutide may be preferred when:
- Maximum weight loss is the therapeutic goal
- Once-weekly dosing improves adherence
- Higher glycemic reduction is needed
- Patient preference for fewer injections
Liraglutide may be preferred when:
- Lower cost or specific insurance coverage favors Victoza/Saxenda
- More gradual dose titration is desired for GI tolerability
- History of intolerance to other GLP-1 RAs
- Daily dosing aligns with established routines
References
Section titled “References”- Wilding JPH, et al. “Once-weekly semaglutide in adults with overweight or obesity (STEP 1).” NEJM 2021;384:989-1002.
- Pi-Sunyer X, et al. “A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE).” NEJM 2015;373:11-22.
- Bain SC, et al. “Semaglutide versus liraglutide in type 2 diabetes (SUSTAIN 7).” Lancet 2017;390:781-792.
- Davies MJ, et al. “Semaglutide 2.4 mg once weekly in adults with overweight or obesity (STEP 2).” Lancet 2021;397:1003-1012.
- le Roux CW, et al. “3 years of liraglutide versus placebo for type 2 diabetes risk reduction (SCALE extension).” Lancet Diabetes Endocrinol 2017;5:118-131.